Physician profile
Daniel E Iwasa
NPI 1750577219
$1,742.52
in general payments reported to CMS, 2019-2025
14 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $85.04 · 2021: $410 · 2022: $185 · 2023: $247 · 2024: $273 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $467.97 | 2022-2025 | Miebo, Infuse, Xiidra |
| Johnson & Johnson Vision Care, INC. | $378.73 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $257.75 | 2019-2024 | Precision 1, Total30 |
| Kala Pharmaceuticals, INC. | $189.30 | 2021-2022 | |
| Dompe US, INC. | $117.69 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $70.22 | 2020-2021 | |
| Shire North American Group INC | $51.97 | 2019 | |
| Biotissue Holdings INC. | $50.30 | 2021-2025 | |
| Oyster Point Pharma, INC. | $35.69 | 2022-2023 | Tyrvaya |
| Optos, INC. | $31.85 | 2019 | |
| Coopervision INC. | $27.50 | 2020-2021 | |
| Sight Sciences, INC. | $25.60 | 2022-2023 | Tearcare System |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $18.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Iwasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.